Mexidol®. Important differences from analogues

Block of articles on this topic

Original and reproduced drugs: what do the clinician need to know?

Author:
A.V. Schulkin, A.A. Filimonova
FSBEI in the Ryazan State Medical University of the Ministry of Health of Russia, Ryazan, Russia

To the question of the evidence base of neuroprotective therapy: Focus on ethylmethylhydroxypyridine succinate

Authors:
A.I. Kochetkov, N.A. Shatalova, M.V. Klepikova, T.V. Filippova, O.D. Ostroumova
FSBEI DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia, Moscow

Reproduced drugs: Benefit ratio/risk

E.A. Ushkalova 1 , S.K. Zyryanov 1.2 , I.A. Gopienko 1
1 FGAOU in Russian University of Friendship of Peoples, Moscow;
2 GBUZ in Moscow "City Clinical Hospital No. 24 of the Department of Health of the city of Moscow", Moscow

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com